ERBB2 and neoplasm: The HER-2/neu(780–788) nonamer has been demonstrated to induce HER2-specific human cytotoxic T lymphocytes capable of lysing HLA-A24+ human tumor cell lines, thus representing a valuable therapeutic target [17,18].